Key result
Chronic daily supplementation with 75 mg of resveratrol for 6 weeks resulted in a 23% increase in flow-mediated dilatation compared with placebo in healthy obese adults (P=0.021).
Why the study?
Does trans-resveratrol 75 mg daily improve flow-mediated dilatation and cognitive performance in healthy obese adults?
RCT (n=28)
double-blind
randomized
Does trans-resveratrol 75 mg daily improve flow-mediated dilatation and cognitive performance in healthy obese adults?
Effect estimate: 23% increase
p-value: p=0.021
Chronic daily resveratrol supplementation improves brachial flow-mediated dilatation in healthy obese adults, suggesting potential benefits for circulatory function.
Supports endothelial function in obese adults; extends RCT evidence for low-dose resveratrol on vascular outcomes.
BACKGROUND: We have previously demonstrated acute dose-dependent increases of flow-mediated dilatation (FMD) in the brachial artery after resveratrol consumption in mildly hypertensive, overweight/obese adults. Resveratrol supplementation has also been shown to increase cerebral blood flow acutely, without affecting cognition. OBJECTIVES: To evaluate the effects of chronic resveratrol supplementation on both FMD and cognitive performance. METHOD: Twenty-eight obese but otherwise healthy adults (BMI: 33.3 ± 0.6 kg/m) were randomized to take a single 75 mg capsule of trans-resveratrol (Resvida) or placebo daily for 6 weeks each in a double-blind crossover supplementation trial. Blood pressure, arterial compliance, FMD, and performance on the Stroop Color-Word Test were assessed at the end of each 6-week intervention period while fasted and at least 18 h after taking the last daily capsule. An additional capsule of the same supplement was then taken. FMD assessment was repeated 1 h later. RESULTS: Chronic resveratrol supplementation for 6 weeks was well tolerated and resulted in a 23% increase in FMD compared with placebo (P=0.021, paired t-test). The extent of increase correlated negatively with baseline FMD (r=-0.47, P=0.01). A single dose of resveratrol (75 mg) following chronic resveratrol supplementation resulted in a 35% greater acute FMD response than the equivalent placebo supplementation. These FMD improvements remained significant after adjusting for baseline FMD. Blood pressure, arterial compliance, and all components of the Stroop Color-Word Test were unaffected by chronic resveratrol supplementation. CONCLUSION: Daily resveratrol consumption was well tolerated and has the potential to maintain healthy circulatory function in obese adults.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2013) conducted an RCT in obese but otherwise healthy adults (n=28). trans-resveratrol vs. placebo was evaluated on flow-mediated dilatation (FMD) and cognitive performance (23% increase, p=0.021). Chronic daily supplementation with 75 mg of resveratrol for 6 weeks resulted in a 23% increase in flow-mediated dilatation compared with placebo in healthy obese adults (P=0.021).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: